PRAME

Revision as of 13:34, 6 September 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Preferentially expressed antigen in melanoma
Identifiers
Symbols PRAME ; MAPE; OIP4
External IDs Template:OMIM5 HomoloGene: 48404
RNA expression pattern
File:PBB GE PRAME 204086 at tn.png
More reference expression data
Orthologs
Template:GNF Ortholog box
Species Human Mouse
Entrez n/a n/a
Ensembl n/a n/a
UniProt n/a n/a
RefSeq (mRNA) n/a n/a
RefSeq (protein) n/a n/a
Location (UCSC) n/a n/a
PubMed search n/a n/a

Preferentially expressed antigen in melanoma, also known as PRAME, is a human gene.[1]

This gene encodes an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, this gene is also expressed in acute leukemias. Five alternatively spliced transcript variants encoding the same protein have been observed for this gene.[1]

References

  1. ↑ 1.0 1.1 "Entrez Gene: PRAME preferentially expressed antigen in melanoma".

Further reading

  • Kirkin AF, Dzhandzhugazyan K, Zeuthen J (1998). "The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes". Exp. Clin. Immunogenet. 15 (1): 19–32. PMID 9619397.
  • Matsushita M, Yamazaki R, Ikeda H, Kawakami Y (2003). "Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies". Leuk. Lymphoma. 44 (3): 439–44. PMID 12688312.
  • Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. PMID 8889548.
  • Ikeda H, Lethé B, Lehmann F; et al. (1997). "Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor". Immunity. 6 (2): 199–208. PMID 9047241.
  • Williams JM, Chen GC, Zhu L, Rest RF (1998). "Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth". Mol. Microbiol. 27 (1): 171–86. PMID 9466265.
  • Neumann E, Engelsberg A, Decker J; et al. (1998). "Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?". Cancer Res. 58 (18): 4090–5. PMID 9751617.
  • van Baren N, Chambost H, Ferrant A; et al. (1998). "PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells". Br. J. Haematol. 102 (5): 1376–9. PMID 9753074.
  • Dunham I, Shimizu N, Roe BA; et al. (1999). "The DNA sequence of human chromosome 22". Nature. 402 (6761): 489–95. doi:10.1038/990031. PMID 10591208.
  • Watari K, Tojo A, Nagamura-Inoue T; et al. (2000). "Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene". FEBS Lett. 466 (2–3): 367–71. PMID 10682862.
  • Pellat-Deceunynck C, Mellerin MP, Labarrière N; et al. (2000). "The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells". Eur. J. Immunol. 30 (3): 803–9. doi:10.1002/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P. PMID 10741395.
  • Matsushita M, Ikeda H, Kizaki M; et al. (2001). "Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia". Br. J. Haematol. 112 (4): 916–26. PMID 11298586.
  • Steinbach D, Hermann J, Viehmann S; et al. (2002). "Clinical implications of PRAME gene expression in childhood acute myeloid leukemia". Cancer Genet. Cytogenet. 133 (2): 118–23. PMID 11943337.
  • Steinbach D, Viehmann S, Zintl F, Gruhn B (2002). "PRAME gene expression in childhood acute lymphoblastic leukemia". Cancer Genet. Cytogenet. 138 (1): 89–91. PMID 12419593.
  • Strausberg RL, Feingold EA, Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.
  • Lehner B, Semple JI, Brown SE; et al. (2004). "Analysis of a high-throughput yeast two-hybrid system and its use to predict the function of intracellular proteins encoded within the human MHC class III region". Genomics. 83 (1): 153–67. PMID 14667819.
  • Oberthuer A, Hero B, Spitz R; et al. (2005). "The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome". Clin. Cancer Res. 10 (13): 4307–13. doi:10.1158/1078-0432.CCR-03-0813. PMID 15240516.
  • Collins JE, Wright CL, Edwards CA; et al. (2005). "A genome annotation-driven approach to cloning the human ORFeome". Genome Biol. 5 (10): R84. doi:10.1186/gb-2004-5-10-r84. PMID 15461802.
  • Gerhard DS, Wagner L, Feingold EA; et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMID 15489334.

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=PRAME&oldid=723311"